Literature DB >> 81513

Possible detection of HLA-DR alloantigenic specificities in man with unabsorbed rabbit antisera.

B G Solheim, A Fuks, L Smith, J L Strominger, E Thorsby.   

Abstract

Thirty-six rabbits were immunized with precipitin lines formed between detergent solubilized membrane fractions from HLA-D-homozygous cells and a rabbit antiserum to human B cells (anti-p 23/30). Thirty-one of the rabbits produced B-cell specific cytotoxic antibodies and twelve of the antibodies were also precipitating in gel diffusion. In cytotoxicity tests six of the antisera showed clear preferential reactivity with the immunizing HLA-D (DR) antigen. Thus immunization of rabbits might prove valuable for the production of HLA-DR typing reagents.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 81513     DOI: 10.1111/j.1365-3083.1978.tb00491.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  Xenoantisera to human DR antigens: Serological and immunochemical characterization.

Authors:  S Ferrone; F Naeim; F Indiveri; L E Walker; M A Pellegrino
Journal:  Immunogenetics       Date:  1978-12       Impact factor: 2.846

2.  Relation between HLA-DR-like antigens and secretory component (SC) in jejunal epithelium of patients with coeliac disease or dermatitis herpetiformis.

Authors:  H Scott; P Brandtzaeg; B G Solheim; E Thorsby
Journal:  Clin Exp Immunol       Date:  1981-05       Impact factor: 4.330

3.  Serological analysis of xenogeneic anti-lymphoblastoid cell-line sera with specificity against HLA-B12.

Authors:  K Schäfer; E D Albert; H Rodt; S Thierfelder
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

Review 4.  The Role of Major Histocompatibility Complex in Organ Transplantation- Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage.

Authors:  Tsukasa Nakamura; Takayuki Shirouzu; Katsuya Nakata; Norio Yoshimura; Hidetaka Ushigome
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.